BR0115423A - Uso de um inibidor de aromatase, uso de exemestano e triptorelina ou um sal destes farmaceuticamente aceitável, e, produto - Google Patents

Uso de um inibidor de aromatase, uso de exemestano e triptorelina ou um sal destes farmaceuticamente aceitável, e, produto

Info

Publication number
BR0115423A
BR0115423A BR0115423-0A BR0115423A BR0115423A BR 0115423 A BR0115423 A BR 0115423A BR 0115423 A BR0115423 A BR 0115423A BR 0115423 A BR0115423 A BR 0115423A
Authority
BR
Brazil
Prior art keywords
aromatase inhibitor
triptorelin
pharmaceutically acceptable
acceptable salt
exemestane
Prior art date
Application number
BR0115423-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dinesh Purandare
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0115423A publication Critical patent/BR0115423A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0115423-0A 2000-11-16 2001-11-06 Uso de um inibidor de aromatase, uso de exemestano e triptorelina ou um sal destes farmaceuticamente aceitável, e, produto BR0115423A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71460500A 2000-11-16 2000-11-16
PCT/US2001/043847 WO2002039995A2 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders

Publications (1)

Publication Number Publication Date
BR0115423A true BR0115423A (pt) 2005-12-13

Family

ID=24870727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115423-0A BR0115423A (pt) 2000-11-16 2001-11-06 Uso de um inibidor de aromatase, uso de exemestano e triptorelina ou um sal destes farmaceuticamente aceitável, e, produto

Country Status (16)

Country Link
EP (1) EP1341549A2 (es)
JP (1) JP2004536022A (es)
KR (1) KR20030051828A (es)
CN (1) CN1498112A (es)
AU (1) AU2002230464A1 (es)
BR (1) BR0115423A (es)
CA (1) CA2428249A1 (es)
CZ (1) CZ20031349A3 (es)
EA (1) EA200300572A1 (es)
IL (1) IL155817A0 (es)
MX (1) MXPA03004195A (es)
NO (1) NO20032206L (es)
NZ (1) NZ525720A (es)
PL (1) PL365904A1 (es)
WO (1) WO2002039995A2 (es)
ZA (1) ZA200303669B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP2010524996A (ja) * 2007-04-23 2010-07-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｂｒｃａ媒介性疾患における使用のための、プロゲステロン受容体拮抗薬と、ルテインホルモン放出ホルモン作動薬および拮抗薬との組み合わせ
CN101775054B (zh) * 2010-02-05 2012-12-26 常州佳尔科药业集团有限公司 4-羟基-4-烯-3-酮甾族化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
WO2002039995A9 (en) 2003-02-06
EA200300572A1 (ru) 2004-06-24
NO20032206L (no) 2003-07-15
NZ525720A (en) 2006-12-22
MXPA03004195A (es) 2003-09-22
WO2002039995A2 (en) 2002-05-23
AU2002230464A1 (en) 2002-05-27
IL155817A0 (en) 2003-12-23
WO2002039995A3 (en) 2003-05-01
ZA200303669B (en) 2004-05-13
NO20032206D0 (no) 2003-05-15
PL365904A1 (en) 2005-01-10
EP1341549A2 (en) 2003-09-10
CN1498112A (zh) 2004-05-19
CZ20031349A3 (cs) 2004-05-12
CA2428249A1 (en) 2002-05-23
JP2004536022A (ja) 2004-12-02
KR20030051828A (ko) 2003-06-25

Similar Documents

Publication Publication Date Title
UA41879C2 (uk) Засіб для лікування мотонейронових захворювань
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
CY1110085T1 (el) Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες
AU747599C (en) Antitumor agents
AR002007A1 (es) UNA COMPOSICION TERAPEUTICA DE APLICACION TOPICA QUE CONTIENE UN ANTAGONISTA DE SUSTANCIA P Y UTILIZACION DE DICHO ANTAGONISTA PARA LAPREPARACIóN DE DICHA COMPOSICION PARA DISMINUIR Y/O ELIMINAR UN EFECTO SECUNDARIO IRRITANTE DE UN PRODUCTO CONTENIDO EN LA MISMA.
ATE304840T1 (de) Hautpflegezusammensetzung
GB9807639D0 (en) Anti-inflammatory agents
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
BRPI0009956A (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
BR0109966A (pt) Combinação de compostos orgânicos
BR0113649A (pt) Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
IL152578A0 (en) Ortho-substituted anthranilic acid amides and their use as medicaments
GB0001449D0 (en) Compositions
BR0113625A (pt) Exemestano como agente de quimioprevenção
BR9612207A (pt) Processo e kit para contracepções em mamíferos fêmeas consistindo de uma combinação de gestageno e estrogênio
BR0115423A (pt) Uso de um inibidor de aromatase, uso de exemestano e triptorelina ou um sal destes farmaceuticamente aceitável, e, produto
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
WO2000001720A3 (en) Compositions and methods for treating papillomavirus-infected cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.